Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity - SPRINT

NCT07070765 is registered in ClinicalTrials.gov with University of Aberdeen as lead sponsor.

NCT NCT07070765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07070765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity - SPRINT
Lead sponsor
University of Aberdeen
Phase
Not applicable
Overall status
Recruiting
Start date
December 12, 2025
Completion date
October 31, 2028
Enrollment
70 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer